Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Clinical trial NCT01915589 · COMPLETED

Trial details

NCT number: NCT01915589
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Hepatocellular

Start date: 2013-09-16
Primary completion: 2014-10-08
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.